ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz Levels in South African HIV/AIDS Patients.
about
Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of AntiretroviralsGenetic variation in the 3'-UTR of CYP1A2, CYP2B6, CYP2D6, CYP3A4, NR1I2, and UGT2B7: potential effects on regulation by microRNA and pharmacogenomics relevance.Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populationsGenetic diversity in black South Africans from SowetoPharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS PatientsNeuronal toxicity of efavirenz: a systematic review.Cytochrome P450 pharmacogenetics in African populations: implications for public health.The pharmacogenetics of opioid therapy in the management of postpartum pain: a systematic review.CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.Functional polymorphisms of xenobiotics metabolizing enzymes-a research topic.CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.Pharmacogenetic considerations for HIV treatment in different ethnicities: an update.Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis.
P2860
Q28069383-763544D9-CFD2-4B04-B3A2-B5A66BA50A4CQ33708471-7C251D69-1419-4A26-8126-40E1C54F9FECQ34756398-23752A11-D761-4666-9105-A02B3D323E71Q34826590-4EC4F5C8-3277-4545-8B21-775DDB76882AQ34995313-E2C028F5-FD91-48A7-AE88-2056F8051678Q35846143-17905557-20CB-4B75-89F4-12A953A3601BQ36437792-ACFE4310-15AB-4B53-BE08-6344C7B3E61FQ38124394-0687168E-3D77-453A-8F56-B1D12DA820C2Q38192688-D342D0A7-6AC3-4EC6-91FD-70B7CFBCE09CQ38664725-BB6AC6A4-D967-464E-9213-BA04026752AFQ38855121-254ABE82-3586-4E0F-8EBA-605803C1BF40Q38861140-1CCCD250-E502-4534-8300-54706D1561F7Q38957969-E0021FBC-02E8-4C14-8C3B-0F79DEE1DE40Q40050910-5E734B60-F9B2-489B-827C-43BD4CA3B5C6Q40492924-486F0355-1989-4D48-B395-BA68460D9647Q41240864-8EEBED7C-9D3D-4CD3-8BDC-C15434566A6CQ47906608-717067E6-6FDD-40BD-8909-3F65A4728B35Q50054098-6D183894-4C60-4C09-AFB5-6F1BCDAF784C
P2860
ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz Levels in South African HIV/AIDS Patients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
ABCB1 4036A>G and 1236C>T Poly ...... uth African HIV/AIDS Patients.
@ast
ABCB1 4036A>G and 1236C>T Poly ...... uth African HIV/AIDS Patients.
@en
type
label
ABCB1 4036A>G and 1236C>T Poly ...... uth African HIV/AIDS Patients.
@ast
ABCB1 4036A>G and 1236C>T Poly ...... uth African HIV/AIDS Patients.
@en
prefLabel
ABCB1 4036A>G and 1236C>T Poly ...... uth African HIV/AIDS Patients.
@ast
ABCB1 4036A>G and 1236C>T Poly ...... uth African HIV/AIDS Patients.
@en
P2093
P2860
P356
P1476
ABCB1 4036A>G and 1236C>T Poly ...... uth African HIV/AIDS Patients.
@en
P2093
Marelize Swart
Peter Smith
P2860
P356
10.3389/FGENE.2012.00236
P577
2012-11-05T00:00:00Z